View Older Stories View More Recent Stories

Aug 5, 2021 08:30AM Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
Aug 4, 2021 07:00AM BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
Aug 3, 2021 10:45AM Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
Jul 19, 2021 08:01AM BioNTech SE (BNTX) to Acquire Kite’s (GILD) Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
Jul 19, 2021 08:00AM BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
Jul 19, 2021 06:26AM Gilead (GILD) Says Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults
Jul 19, 2021 06:26AM Gilead (GILD) Says New Phase 3 Data Support Sustained, Long-Acting Efficacy of Lenacapavir, its Investigational HIV-1 Capsid Inhibitor
Jul 17, 2021 06:01AM New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor
Jul 17, 2021 06:01AM Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults
Jul 15, 2021 04:05PM Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021
Jul 12, 2021 07:30AM Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research
Jun 28, 2021 04:09PM Gilead Sciences (GILD) Submits NDA to FDA for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
Jun 28, 2021 04:09PM Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Opt
Jun 28, 2021 08:36AM Gilead's(GILD) Kite Announces Yescarta CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line R/R Large B-cell Lymphoma
Jun 28, 2021 08:30AM Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
Jun 24, 2021 09:00AM Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
Jun 23, 2021 08:43AM Gilead Sciences' (GILD) Kite Joint Venture Gains the First CAR T-cell Therapy Approval in China
Jun 23, 2021 08:40AM Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China
Jun 21, 2021 08:03AM Gilead's (GILD) Veklury Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
Jun 21, 2021 08:00AM Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
Jun 21, 2021 04:00AM Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
Jun 17, 2021 09:04AM Gilead Sciences' (GILD) Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
Jun 17, 2021 09:00AM Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
Jun 12, 2021 10:00AM Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis
Jun 10, 2021 05:02PM Gilead (GILD) Announces FDA Approves New Formulation of Epclusa, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
Jun 10, 2021 05:00PM U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
Jun 4, 2021 02:30PM Gilead (GILD) Announces Kite's Tecartus Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
Jun 4, 2021 02:30PM Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
Jun 4, 2021 09:05AM Gilead Sciences (GILD) Trodelvy Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Jun 4, 2021 09:00AM Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
May 19, 2021 05:00PM Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021
May 14, 2021 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
May 6, 2021 04:09PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 29, 2021 04:02PM Gilead Sciences Announces Second Quarter 2021 Dividend
Apr 26, 2021 06:34PM Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India
Apr 19, 2021 02:55AM Dispersion Holdings PLC Intention to Float on AQSE Growth Market
Apr 15, 2021 04:05PM Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021
Apr 13, 2021 05:43PM Gilead Sciences (GILD) Confirms U.S. FDA Granted Accelerated Approval to Trodelvy for Treatment of Metastatic Urothelial Cancer
Apr 13, 2021 05:42PM U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Apr 8, 2021 06:18AM Gilead Sciences (GILD) Announces FDA Approves Trodelvy, the First Treatment for Metastatic TNBC Shown to Improve PFS and OS
Apr 7, 2021 07:53PM FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
Apr 1, 2021 04:17PM Gilead's (GILD) Kite Submits sBLA to FDA for Tecartus in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Apr 1, 2021 04:15PM Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Mar 31, 2021 12:26AM Gilead Sciences Comments on the Passing of John C. Martin, PhD
Mar 26, 2021 08:34AM Gilead Sciences (GILD) Appoints Flavius Martin, MD as Executive Vice President, Research
Mar 26, 2021 08:30AM Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research
Mar 25, 2021 04:01PM Gilead Sciences (GILD) Announces EMA Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
Mar 25, 2021 04:01PM European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
Mar 18, 2021 06:17AM Gilead Sciences (GILD), Novo Nordisk (NVO) Expand NASH Clinical Collaboration
Mar 18, 2021 05:00AM Gilead and Novo Nordisk Expand NASH Clinical Collaboration
View More Recent Stories View Older Stories